@twi...
Quoting you: "no one except
a few dozen readers of this message board
is anticipating an interim stop.
the unexpected good news will be, no futility stop,
while the market has priced one in."
Hopefully you are including me (excuse me..can not help it)
" We few. We precious few. We band of brothers"
Henry V...W. Shakespeare
While I am a fan of "abridged notes", I believe you are pushing the envelope here. Two points...There has been a land-swell of positive information recently supporting n-3s as having beneficial effects on CVD risk..Anyone betting big money on this binary event would have to be brave indeed to imagine results bad enough to halt for futility..The other point is that trials halted for futility at interim usually are halted not because the drug is useless, but rather the drug is dangerous. If there were serious AEs (non CVD adverse events)) we would know about them already, as these AEs are unblinded to the sponsor and FDA.
Indeed futility would fly in the face not only of JELIS, but that of Japan itself and Greenland and the Eskimos. It would counterfeit the eicosanoid system and suggest there was some cryptic metabolic system that has thus far evaded all scientific and medical radar...And believe me discovering the eicosanoid system was one of the greatest scientific detective stories...
I wish there would be an up sweep of the PPS if not halted, but I think we will see the PPS back at these levels...
JMO..Regards...@JL
Market Data 
Markets 
AI
